Innate Pharma (OTCMKTS:IPHYF) Shares Up 57.2% – Should You Buy?

Innate Pharma SA (OTCMKTS:IPHYF)’s stock price rose 57.2% on Monday . The stock traded as high as $2.06 and last traded at $2.06. Approximately 300 shares changed hands during trading, The stock had previously closed at $1.31.

Innate Pharma Trading Up 57.2%

The company has a fifty day moving average of $1.53 and a two-hundred day moving average of $2.00.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.